Loading
A phase 3 trial of Tusamitamab ravtansine and Docetaxel in Non-small-cell lung cancer, run by Sanofi, recorded as terminated on the registry.
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients is a phase 3 interventional study registered as NCT04154956 by Sanofi, with 389 participants recorded, started 2020-02-06 and due to reach its primary completion in 2023-09-22. Interventions recorded: SAR408701, Docetaxel. Conditions recorded: Non-small Cell Lung Cancer Metastatic.
Linked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
389 enrolled.
95% CI 3.713 to 6.998; Figures from the ClinicalTrials.gov results section (first posted 2024-11-01), not from a publication · 95% CI 5.520 to 7.359
Source95% CI 11.795 to 14.160; Figures from the ClinicalTrials.gov results section (first posted 2024-11-01), not from a publication · 95% CI 8.936 to 15.244
Source95% CI 16.04 to 28.26; Figures from the ClinicalTrials.gov results section (first posted 2024-11-01), not from a publication · 95% CI 18.13 to 30.84
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS)primary | Tusamitamab Ravtansine | 194 | 5.39 months | 1.143 (0.864 to 1.512) | 0.8204 | link |
| Docetaxel | 195 | 5.85 months | ||||
| Overall Survival (OS)primary | Tusamitamab Ravtansine | 194 | 12.81 months | 0.846 (0.644 to 1.109) | 0.1120 | link |
| Docetaxel | 195 | 11.53 months | ||||
| Objective Response Rate (ORR) | Tusamitamab Ravtansine | 189 | 21.7% | - | 0.6972 | link |
| Docetaxel | 187 | 24.1% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tusamitamab ravtansine, Sanofi and the tag pipeline.
Shares Tusamitamab ravtansine, Sanofi, Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
Shares Sanofi, Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/